{"prompt": "['Abbreviated Title: Ph II SGI110 in Peds & Adults', '43', 'Version Date: 07/22/2019', 'notification phoned in must be entered electronically into CTEP-AERS by the original submitter', 'at the site.', '9.3.2 Distribution of Adverse Event Reports', 'CTEP-AERS is programmed for automatic electronic distribution of reports to the following', 'individuals: Principal Investigator and Adverse Event Coordinator(s) (if applicable) of the', 'Corresponding Organization or Lead Organization, the local treating physician, and the Reporter', 'and Submitter. CTEP-AERS provides a copy feature for other e-mail recipients.', '9.3.3 Expedited Reporting Guidelines', 'Use the NCI protocol number and the protocol-specific patient ID assigned during trial', 'registration on all reports.', 'Note: A death on study requires both routine and expedited reporting, regardless of', 'causality. Attribution to treatment or other cause must be provided.', 'Death due to progressive disease should be reported as Grade 5 \"Disease progression\" in the', 'system organ class (SOC) \"General disorders and administration site conditions.\" Evidence that', 'the death was a manifestation of underlying disease (e.g., radiological changes suggesting tumor', 'growth or progression: clinical deterioration associated with a disease process) should be', 'submitted.', 'Phase 1 and Early Phase 2 Studies: Expedited Reporting Requirements for Adverse', 'Events that Occur on Studies under an IND/IDE within 30 Days of the Last Administration', 'of the Investigational Agent/Intervention 1,2', 'FDA REPORTING REQUIREMENTS FOR SERIO US ADVERSE EVENTS (21 CFR Part 312)', 'NOTE: Investigators MUST immediately report to the sponsor (NCI) ANY Serious Adverse Events, whether or not they are', 'considered relatedto the investigational agent(s)/intervention (21 CFR 312.64)', 'An adverse event is considered serious if it results in ANY of the following outcomes:', '1) Death', '2) A life-threatening adverse event', '3) An adverse event that results in inpatient hospitalization or prolongation of existing hospitalization for> 24 hours', '4)', 'A', 'persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions', '5) A congenital anomaly/birth defect.', '6) Important Medical Events (IME) that may not result in death, be life threatening, or require hospitalization may be', 'considered serious when, based upon medical judgment, they may jeopardize the patient or subject and may require', 'medical or surgical intervention to prevent one of the outcomes listed in this definition. (FDA, 21 CFR 312.32; ICH', 'E2A and ICH E6).', 'ALL SERIO US adverse events that meet the above criteria MUST be immediately reported to the NCI via AdEERS within', 'the timeframes detailed in the table below.', 'Grade 3-5', 'Hospitalization', 'Grade 1 and Grade 2 Timeframes', 'Timeframes']['Abbreviated Title: Ph II SGI110 in Peds & Adults', '44', 'Version Date: 07/22/2019', 'Resulting in', 'Hospitalization >', '10 Calendar Days', '24 hrs', '24-Hour 5 Calendar Days', 'Not resulting in', 'Hospitalization >', 'Not required', '24 hrs', 'NOTE: Protocol-specific exceptions to expedited reporting of serious adverse events are found in the Specific Protocol', 'Exceptions to Expedited Reporting (SPEER) portion of the CAEPR.', 'Expedited AE reporting timelines are de fined as:', '\"24-Hour; 5 Calendar Days\" - The AE must initially be reported via AdEERS within 24 hours of learning of the', 'AE, followed by a complete expedited report within 5 calendar days of the initial 24-hour report.', '\"10 Calendar Days\" - A complete expedited report on the AE must be submitted within 10 calendar days of', 'learning of the AE.', '1Serious adverse events that occur more than 30 days after the last administration of investigational agent/intervention', 'and have an attribution of possible, probable, or definite require reporting as follows:', 'Expedited 24-hour notification followed by complete report within 5 calendar days for:', 'All Grade 3, 4, and Grade 5 AEs', 'Expedited 10 calendar day reports for:', 'Grade 2 AEs resulting in hospitalization or prolongation of hospitalization', '2 For studies using PET or SPECT IND agents, the AE reporting period is limited to 10 radioactive half-lives, rounded', 'UP to the nearest whole day, after the agent/intervention was last administered. Footnote \"1\" above applies after this', 'reporting period.', 'Effective Date: May 5, 2011', '9.4 ROUTINE ADVERSE Event REPORTING TO CTEP', 'All Adverse Events must be reported in routine study data submissions. AEs reported', 'expeditiously through CTEP-AERS must also be reported in routine study data', 'submissions.', '9.5 SECONDARY MALIGNANCY', 'A secondary malignancy is a cancer caused by treatment for a previous malignancy (e.g.,', 'treatment with investigational agent/intervention, radiation or chemotherapy). A secondary', 'malignancy is not considered a metastasis of the initial neoplasm.', 'CTEP requires all secondary malignancies that occur following treatment with an agent under an', 'NCI IND/IDE be reported via CTEP-AERS. Three options are available to describe the event:', 'Leukemia secondary to oncology chemotherapy (e.g., acute myelocytic leukemia [AML])', 'Myelodysplastic syndrome (MDS)', 'Treatment-related secondary malignancy', 'Any malignancy possibly related to cancer treatment (including AML/MDS) should also be', 'reported via the routine reporting mechanisms outlined in each protocol.']\n\n###\n\n", "completion": "END"}